<DOC>
	<DOCNO>NCT01641536</DOCNO>
	<brief_summary>This study open label , dose escalation study use classical 3+3 design determine MTD HB-110 ass safety , immunogenicity efficacy HB-110 DNA therapeutic vaccine administer Electroporation combination Entecavir chronic hepatitis B patient .</brief_summary>
	<brief_title>Tolerability , Immunogenicity Efficacy HB-110 Administered Electroporation Chronic Hepatitis B Patients</brief_title>
	<detailed_description>The patient enrol trial successively allocate three cohort HB-110 1mg , 2mg , 4mg combination Entecavir accord classical 3+3 protocol design . They administer Electroporation device . The scheduled assessment visit carry three period : run-in period , treatment period , follow-up period . The run-in period include screen visit write informed consent obtain screening period patient assessed eligibility . It complete within 14 day prior Visit 1 . The patient meet inclusion criterion start treatment period . During treatment period , subject administer HB-110 Electroporation visit combination antiviral drug , Entecavir . The Follow-up period start subject complete treatment period continue follow-up visit .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Agreed female subject female partner male subject pregnant study . Chronic hepatitis B patient take Entecavir Screening Visit 6 month longer Have use IFN alpha antiviral drug within previous 6 month treat hepatitis . Have blood HBV DNA level â‰¤300 copies/mL determine Screening Visit Have ALT level less equal 2 time upper limit normal [ ULN ] Screening Visit Provide sign voluntary write informed consent study participation Who participate study within previous 30 day Screening Visit Have follow decompensated liver parameter , serum albumin level &lt; 3 g/dL , total bilirubin level &gt; 2.5 mg/dL , international normalize ratio ( INR ) &gt; 1.8 Do adequate renal function determine serum creatinine level 1.5 time normal range ( 1.2 mg/dL ) Had previous liver transplant bone marrow transplant Are currently take immunosuppressive possible immunomodulatory drug Women pregnant breastfeed female subject pregnant breastfeed study History allergy/hypersensitivity drug Any clinically significant acute chronic unstable renal , cardiac endocrine disease ( e.g. , cardiac failure , renal failure , pancreatitis , diabetes mellitus ) Presence primary secondary hepatic disease ( e.g. , hemochromatosis , Wilson 's disease , alcoholic hepatic disease , non alcoholic fatty liver , alpha1antitrypsin deficiency ) hepatitis B Who observe hepatocellular mass ultrasonography abnormal increase serum AFP Past present history hepatocarcinoma History grand mal epilepsy , currently antiepileptic medication Occurrence least one episode syncope within last 12 month Presence implantable cardiac device ( pacemaker , automate implantable cardioverter defibrillator [ AICD ] ) implantable nerve stimulator Who arrhythmia Any condition consider inappropriate study Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>DNA Virus Infections</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Liver</keyword>
	<keyword>Chronic Disease</keyword>
	<keyword>HBV</keyword>
</DOC>